more_reports

PFAS Treatment System Processes 2 Million Gallons at New Jersey Site

  ()
BioLargo's AEC technology has treated over 2 million gallons of PFAS-contaminated water in New Jersey while meeting regulatory standards. Learn how the system reduces waste and costs compared with traditional methods.
Tags: CleantechTechnologySpecial Situations

This AI Healthcare Platform Is Taking Its New York Expansion Through 2029

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its EngageWell partnership after an initial virtual-care pilot connected more than 400 underserved New Yorkers with physician-led care.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

Cleantech Company Delivers PFAS Removal Breakthrough in New Jersey

  ()
BioLargo Inc. (BLGO:OTCQX) announces the processing of more than 2 million gallons of PFAS-contaminated water using its patented Aqueous Electrostatic Concentrator (AEC) technology. Find out why one technical analyst likes BLGO's business model.
Tags: CleantechTechnologySpecial Situations

Evommune Doses First Patient in Migraine Trial

  ()
Evommune Inc. (EVMN:NYSE) dosed its first patient in a Phase 2b trial of EVO756, an oral migraine prevention drug targeting the MRGPRX2 receptor.
Tags: Biotechnology / Pharmaceuticals

Karyopharm Pursues Myelofibrosis FDA Milestone

  ()
Karyopharm Therapeutics Inc. (KPTI:NASDAQ) prepares an FDA filing for selinexor plus ruxolitinib after Phase 3 results, targeting the first approved combination therapy for myelofibrosis.
Tags: Biotechnology / Pharmaceuticals

Sarepta Grants New CEO 2.2M Stock Options Amid "Sell" Rating

  ()
Sarepta Therapeutics Inc. (SRPT:NASDAQ) granted CEO Michael Severino options for 2,224,342 shares and 756,104 RSUs as an inducement award tied to his hiring.
Tags: Biotechnology / Pharmaceuticals

Digital Health Firm Launches Integrated GLP-1 Program

  ()
DarioHealth integrates its digital platform with licensed providers to offer end-to-end GLP-1 support. See how the new program targets employers and health plans in a growing market.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

New GLP-1 Platform Combines Doctor Prescriptions, AI Coaching and Chronic Care

  ()
DarioHealth Corp. (NASDAQ: DRIO) introduced its Integrated GLP-1 Program, bringing licensed provider evaluations, FDA-approved GLP-1 prescribing where clinically appropriate and ongoing care into one experience.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Dyadic C1 Platform Delivers Ebola Antigens in 15 Days

  ()
Dyadic International produced two Bundibugyo ebolavirus antigens in about 15 days using its C1 platform and delivered them for preclinical testing amid an active outbreak in Africa.
Tags: Biotechnology / Pharmaceuticals

Biotech Produces Ebola Proteins in Just 15 Days as African Outbreak Intensifies

  ()
Dyadic International Inc. (NASDAQ: DYAI) has rapidly developed and produced recombinant protein antigens targeting Bundibugyo ebolavirus, progressing from receipt of the plasmids to purified proteins in approximately 15 days. As the Ebola outbreak in Africa continues, this achievement highlights the speed and potential of Dyadics C1 protein-production platform. Read why one technical analyst believes DYAIs' stock could be positioned for a bullish move.
Tags: Biotechnology / Pharmaceuticals

Blood in the Streets: Why I'm Buying Gold Miners, a Peru Tailings Giant, and Two Biotech 10-Baggers This Summer

Contributed Opinion
  ()
Newsletter writer Chen Lin shares his view on the current state of the market and shares some stocks on his list.
Tags: GoldBiotechnology / PharmaceuticalsTechnologyCopperSilver

Wet AMD Drug Secures First FDA-Approved Bevacizumab Status

  ()
Outlook Therapeutics gains FDA approval for LYTENAVA, the first ophthalmic bevacizumab for wet AMD. The approval opens access to an $8.5 billion U.S. market with 12 years of exclusivity expected.
Tags: Biotechnology / Pharmaceuticals

FDA Approves First Ophthalmic Treatment for Wet AMD, Leading Wainwright to Triple Price Target

  ()
Outlook Therapeutics Inc.'s (OTLK:NASDAQ) LYTENAVA received FDA approval as the first ophthalmic bevacizumab for wet AMD, with U.S. launch targeted by year-end 2026
Tags: Biotechnology / Pharmaceuticals

Smith & Nephew Expands Wound Care Portfolio in $22B Market

  ()
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Melanoma Biotech Secures Nasdaq Listing via All-Share Merger

  ()
Scancell advances its iSCIB1+ melanoma program toward Phase 3 after agreeing to an all-share merger that brings Nasdaq access and up to $89 million in new financing.
Tags: Biotechnology / Pharmaceuticals

Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing

  ()
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Scancell, Neuphoria Agree to All-Share Merger

  ()
Neuphoria Therapeutics Inc. (NEUP:NASDAQ) and Scancell Holdings Plc (SCNLF:OTC; SCLP:AIM) agreed to an all-share merger, listing the combined company on Nasdaq while funding a Phase 3 melanoma trial.
Tags: Biotechnology / Pharmaceuticals

Novocure Hits Record Revenue and Raises 2026 Outlook

  ()
Novocure posts record Q2 revenue of $183.6 million and lifts full-year guidance after Optune Pax earns CE Mark approval in Europe. See the key catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Novocure Posts Record Q2 Revenue of US$183.6M

  ()
Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million.
Tags: Biotechnology / Pharmaceuticals

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Research Report
  ()
A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety."
Tags: Biotechnology / Pharmaceuticals

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

  ()
PolyPid enters a major commercialization deal with Azurity for D-PLEX100 targeting surgical site infections, with upfront payments and milestone potential supporting retail investors watching PYPD progress toward 2027 launch.
Tags: Biotechnology / Pharmaceuticals